Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...

Advancements and Projections in the Global Pulmonary Arterial Hypertension Market: Insights, Trends, Opportunities, and ...

An independent data monitoring committee has recommended terminating the ZENITH study early based on the results.

Winrevair lowered death or transplant risk in adults with PAH functional class 3-4 at high risk of dying; all in study may ...

Significantly higher levels of the miRNA molecule miR-3591-5p were seen in those with CHD and moderate to severe PAH than ...

XOMA Royalty Corp. (XOMA), a biotechnology royalty aggregator, Monday announced that it now owns royalty and milestone interest in ...

Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...

Recent health news highlights major developments in pharmaceuticals, including Merck's promising Winrevair for pulmonary ...

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in ...

Royalty Corporation now owns an economic interest in seralutinib, a Phase 3 asset being studied in pulmonary arterial hypertension ...